Electronic clinical outcome assessments (eCOA) have become essential for modern clinical trials, offering numerous advantages over traditional paper-based methods. However, the benefits of eCOA can only be fully realized if the data collected is of the highest quality. Ensuring data quality in eCOA clinical trials requires a multifaceted approach, encompassing platform design, patient engagement strategies, robust data validation procedures, and strict adherence to regulatory guidelines. This blog post explores key strategies for achieving and maintaining data quality throughout the eCOA process.

‍

In the rapidly evolving landscape of oncology clinical trials, the integration of electronic Clinical Outcome Assessments (eCOA) and wearable technologies is revolutionizing how data is collected and patient experiences are monitored. These technologies offer unprecedented opportunities to enhance data quality, improve patient engagement, and enable real-time tracking of treatment efficacy and side effects. This blog post delves into the pivotal roles that eCOA and wearables play in modern oncology clinical trials, highlighting their impact on patient-centric research and the advancement of cancer care.

‍

Explore the prevalent challenges encountered in eCOA clinical trials, from technical issues and patient adherence to data security and regulatory adherence, and discover strategies for mitigation.

When talking to customers conducting their first multi-country trial, we sometimes liken clinical trials to spider webs. Just as a garden spider’s web differs from a black widow’s, clinical trials follow unique patterns in every region. Each country comes with its own set of rules, ethical standards, approval processes, and data privacy laws. Cultural factors also play a crucial role in how patients are recruited and understand Clinical trials, requiring sensitive communication and a deep respect for participants’ needs.

In Japan, these regulatory and cultural intricacies form a complex ‘web,’ with anchor points and structural requirements that, when understood and implemented correctly, create a framework for success. However, conducting Clinical trials in Japan has historically posed challenges for Sponsors and Contract Research Organizations (CROs). When we first entered the region, one Sponsor consistently cited issues with eCOA solutions and site and patient support, not fully adapting to Japan’s unique requirements. This feedback, combined with our own experiences on the ground, revealed a clear need for improvement.

Today, we can proudly say that the solutions we put in place have transformed Japan’s Clinical trial landscape, and what was once a challenge has now become the “gold standard” for supporting Clinical trials in the region.

‍

This year’s Scope Summit once again brought thousands in the clinical research space together, offering a glimpse into the evolving operational and technological landscapes shaping the future of trials.  

‍

The J.P. Morgan Healthcare Conference returned to San Francisco this year, bringing significant deals and strategic shifts that signal where healthcare is headed. While this year’s weather outside was dry and sunny, a substantial change from the prior two years' rainy conferences, the conditions inside differed, with several companies making waves. 

‍

Medable’s 2024 was a year of exceeding key milestones and helping our customers reach new heights.

Take a look at the difference Medable has made with our year-end impact report.

‍

‍

‍

‍

‍

In November, we released an update to Medable Studio titled Medable AI. This latest update furthers Studio's unique value proposition, offering sponsors and CROs unprecedented control over the study creation and launch process, as well as scalability, speed, and streamlining of operations.  This provides the easiest, fastest path to study launch in the industry to date.

If this already sounds like something you could use, check out a demo or an in-depth look at its feature set here. 

For everyone else, read below to discover what exactly Medable AI has to offer.

‍

Our world is drowning in data. 

Humanity generates a staggering 402.74 million terabytes of information every day. From the countless videos we stream to the endless social media scrolling, our global digital footprint is growing exponentially. This data deluge is reshaping industries, influencing our lives, and posing unprecedented challenges. 

Within clinical trials, rapidly evolving technologies are enabling researchers to capture new data points as trials grow more complex. However, this poses new challenges in managing clinical trial data. 

‍

A decade ago, our founders’ experiences in clinical research and life sciences drove them to create Medable, a simple cloud-based platform that could improve theconduct of trials. Over the last ten years, we’ve conducted nearly 400 trials on our platform, continually refining it to provide a better experience for sites, patients, and caregivers.Today, we’re excited to announce that our customers are entering a new era of control, ease of use, and simplicity.

‍

A top-10 pharmaceutical company was looking to reduce the amount of administrative burden on their clinical trial sites and themselves.  The sponsor sought to find a vendor that could use one eConsent system to manage paper and electronic consent.  Additionally, they sought to use the central eConsent system to populate the clinical trial sites’ IRB and EDC systems,  as well as some internal systems.

‍